StreetInsider.com News Articles

NeoGenomics expands digital pathology deal with Indica Labs

Thu, 15 Oct 2026 07:06:58 -0400

NeoGenomics, Inc. (NASDAQ: NEO) has expanded its partnership with Indica Labs to scale its digital pathology infrastructure using AI-driven diagnostic tools, according to a press release from the Fort Myers, Florida-based company.

NeoGenomics selected the Indica Labs HALO AP® platform to underpin its digital pathology operations through a cloud-based framework. The vendor-neutral image management system is designed to allow NeoGenomics to incorporate third-party or internally developed AI tools while limiting integration costs. The platform is intended to give customers access to digital pathology capabilities without requiring significant capital investment or complex IT integration.

The two companies have had a technology relationship since

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

Thu, 15 Oct 2026 07:05:00 -0400

The collaboration is designed to support faster, more informed care for patients and providers

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a provider of oncology diagnostic solutions that enable precision medicine across the cancer care continuum, has expanded its partnership with Indica Labs, a global leader in AI-powered digital pathology. The collaboration is intended to scale NeoGenomics' digital pathology infrastructure and accelerate AI-driven diagnostics across its enterprise, giving healthcare providers and their patients more timely, consistent access to advanced diagnostic insight.

NeoGenomics selected the Indica Labs HALO AP® platform to enable its digital pathology operations through a

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

Thu, 15 Oct 2026 07:05:00 -0400

The collaboration is designed to support faster, more informed care for patients and providers

NeoGenomics selected the Indica Labs HALO AP® platform to enable its digital pathology operations through a

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026

Wed, 14 Oct 2026 07:05:00 -0400

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights.

The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026

Wed, 14 Oct 2026 07:05:00 -0400

The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be

Piper Sandler: 'Neogenomics (NEO) Is Winning the Community'

Wed, 07 Oct 2026 09:14:22 -0400

Piper Sandler analyst David Westenberg reiterated an Overweight rating on Neogenomics (NASDAQ: NEO).

The analyst commented: "NEO Is Winning the Community; NEO wins on service and menu, not the newest test. Our checks suggest NEO is a unique oncology lab that offers the full menu of tests with good customer service. We believe winning in the community setting is less about having the best or newest test and more about delivering a menu and service that are easy for the physician to use; in practice, a community oncologist wants someone at the lab to call and explain a result more than

Neogenomics (NEO) PT Raised to $20 at StoneX

Tue, 06 Oct 2026 08:09:43 -0400

StoneX analyst Bruce Jackson raised the price target on Neogenomics (NASDAQ: NEO) to $20.00 (from $16.00) while maintaining a Buy rating.

Neogenomics (NEO) PT Raised to $22 at Needham

Tue, 06 Oct 2026 07:11:40 -0400

Needham analyst Mike Matson raised the price target on Neogenomics (NASDAQ: NEO) to $22.00 (from $19.00) while maintaining a Buy rating.

The analyst comments "Yesterday, after the close, NEO announced a CEO transition plan. Warren Stone, who currently serves as President and Chief Operating Officer (COO), will replace current CEO Tony Zook, effective 1/4/27. NEO also guided to 3Q26 revenue of $209M (up ~11% Y/Y reported), above consensus of $206M, and guided to NGS revenue growth of ~28% Y/Y (vs. NGS growth of 26% Y/Y in 2Q26). NEO reiterated its 2026 revenue and adjusted EBITDA guidance of $802-806M and $56-58M, respectively.

Neogenomics (NEO) PT Raised to $22 at Needham

Tue, 06 Oct 2026 07:11:40 -0400

Needham analyst Mike Matson raised the price target on Neogenomics (NASDAQ: NEO) to $22.00 (from $19.00) while maintaining a Buy rating.

BTIG Upgrades Neogenomics (NEO) to Buy

Tue, 06 Oct 2026 05:54:07 -0400

BTIG analyst Mark Massaro upgraded Neogenomics (NASDAQ: NEO) from Neutral to Buy with a price target of $28.00.

The analyst comments "We upgrade NeoGenomics from a Neutral to a Buy rating and establish a $28 PT on the stock. It has been impossible to ignore the surge in valuations across the precision oncology lab space and shares of NEO, while up 62% YTD, trade at just ~3x Street's 2027 consensus revenues, well below its SMID cap peer specialty labs that trade at ~11x. Our primary call is that the stock is simply too cheap, and we expect the stock to re-rate

BTIG Upgrades Neogenomics (NEO) to Buy

Tue, 06 Oct 2026 05:54:07 -0400

BTIG analyst Mark Massaro upgraded Neogenomics (NASDAQ: NEO) from Neutral to Buy with a price target of $28.00.

BTIG Upgrades Neogenomics (NEO) to Buy

Tue, 06 Oct 2026 05:54:07 -0400

BTIG analyst Mark Massaro upgraded Neogenomics (NASDAQ: NEO) from Neutral to Buy with a price target of $28.00.

BTIG Upgrades Neogenomics (NEO) to Buy

Tue, 06 Oct 2026 05:54:07 -0400

BTIG analyst Mark Massaro upgraded Neogenomics (NASDAQ: NEO) from Neutral to Buy with a price target of $28.00.

Form 4 NEOGENOMICS INC For: Oct 01 Filed by: Stone Warren

Mon, 05 Oct 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20261005/27149174.html

Form 8-K NEOGENOMICS INC For: Oct 05

Mon, 05 Oct 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20261005/27148830.html

NeoGenomics names Warren Stone as CEO, effective January 2027

Mon, 05 Oct 2026 16:06:31 -0400

NeoGenomics, Inc. (NASDAQ: NEO) announced a planned executive leadership transition, with Warren Stone, current President and Chief Operating Officer, set to become Chief Executive Officer and a member of the Board of Directors effective January 4, 2027.

Current CEO Tony Zook will remain in his role through January 3, 2027, and will then assume the position of Executive Chairman. Lynn Tetrault, who has served as Chair and Board member since 2015, will step down as Chair on January 4, 2027, continue as an independent director until the 2027 Annual Meeting of Stockholders, and will not stand for reelection at that meeting.

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

Mon, 05 Oct 2026 16:05:00 -0400

Warren Stone, current President and COO, to become CEO and a member of the Board effective January 4, 2027
Tony Zook to remain CEO through January 3, 2027, and become Executive Chairman effective January 4, 2027
Lynn Tetrault, current Chair and Board member since 2015, to step down as Chair effective January 4, 2027, continue to serve as an independent director until the 2027 Annual Meeting of Stockholders, and not stand for reelection at that meeting
Michael Kelly to serve as Lead Independent Director effective January 4, 2027
Preliminary unaudited third quarter revenue is expected to be approximately $209 million, with NGS revenue

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

Mon, 05 Oct 2026 16:05:00 -0400

Warren Stone, current President and COO, to become CEO and a member of the Board effective January 4, 2027
Tony Zook to remain CEO through January 3, 2027, and become Executive Chairman effective January 4, 2027
Lynn Tetrault, current Chair and Board member since 2015, to step down as Chair effective January 4, 2027, continue to serve as an independent director until the 2027 Annual Meeting of Stockholders, and not stand for reelection at that meeting
Michael Kelly to serve as Lead Independent Director effective January 4, 2027
Preliminary unaudited third quarter revenue is expected to be approximately $209 million, with NGS revenue

Gentherm completes acquisition of Modine's Performance Technologies unit

Thu, 01 Oct 2026 16:36:45 -0400

Gentherm (NASDAQ: THRM) has completed its acquisition of Modine's Performance Technologies business through a Reverse Morris Trust transaction, the company announced Oct. 1, 2026. The deal was first announced Jan. 29, 2026.
Under the transaction terms, Modine (NYSE: MOD) shareholders received 0.44619 shares of Gentherm common stock for each share of Modine common stock held as of Sept. 28, 2026. Following the close, former Modine shareholders own approximately 43.62% of the combined company, while existing Gentherm shareholders hold approximately 56.38%, excluding any overlapping ownership.
Modine received a cash distribution of approximately $156 million from the spun-off subsidiary, which was used to repay

Gentherm completes acquisition of Modine's Performance Technologies unit

Thu, 01 Oct 2026 16:36:45 -0400

Gentherm (NASDAQ: THRM) has completed its acquisition of Modine's Performance Technologies business through a Reverse Morris Trust transaction, the company announced Oct. 1, 2026. The deal was first announced Jan. 29, 2026.
Under the transaction terms, Modine (NYSE: MOD) shareholders received 0.44619 shares of Gentherm common stock for each share of Modine common stock held as of Sept. 28, 2026. Following the close, former Modine shareholders own approximately 43.62% of the combined company, while existing Gentherm shareholders hold approximately 56.38%, excluding any overlapping ownership.
Modine received a cash distribution of approximately $156 million from the spun-off subsidiary, which was used to repay

Gentherm completes acquisition of Modine's Performance Technologies unit

Thu, 01 Oct 2026 16:36:45 -0400

Gentherm (NASDAQ: THRM) has completed its acquisition of Modine's Performance Technologies business through a Reverse Morris Trust transaction, the company announced Oct. 1, 2026. The deal was first announced Jan. 29, 2026.
Under the transaction terms, Modine (NYSE: MOD) shareholders received 0.44619 shares of Gentherm common stock for each share of Modine common stock held as of Sept. 28, 2026. Following the close, former Modine shareholders own approximately 43.62% of the combined company, while existing Gentherm shareholders hold approximately 56.38%, excluding any overlapping ownership.
Modine received a cash distribution of approximately $156 million from the spun-off subsidiary, which was used to repay

Gentherm completes acquisition of Modine's Performance Technologies unit

Thu, 01 Oct 2026 16:36:45 -0400

Gentherm (NASDAQ: THRM) has completed its acquisition of Modine's Performance Technologies business through a Reverse Morris Trust transaction, the company announced Oct. 1, 2026. The deal was first announced Jan. 29, 2026.
Under the transaction terms, Modine (NYSE: MOD) shareholders received 0.44619 shares of Gentherm common stock for each share of Modine common stock held as of Sept. 28, 2026. Following the close, former Modine shareholders own approximately 43.62% of the combined company, while existing Gentherm shareholders hold approximately 56.38%, excluding any overlapping ownership.
Modine received a cash distribution of approximately $156 million from the spun-off subsidiary, which was used to repay

Gentherm Completes Combination with Modine’s Performance Technologies Business

Thu, 01 Oct 2026 16:36:00 -0400

Combination Creates Global Market Leader of Thermal and Precision Flow Management Technologies

Announces Appointment of Paul Mascarenas to its Board of Directors

NOVI, Mich., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM) (the “Company” or “Gentherm”), a global market leader of thermal and precision flow management technologies, today announced it has completed the previously announced combination with Modine’s Performance Technologies business (the “Business”). The transaction was first announced on January 29, 2026.

"Today marks the start of the next phase for Gentherm. Together, we have created a global leader in thermal and precision

Gentherm Completes Combination with Modine’s Performance Technologies Business

Thu, 01 Oct 2026 16:36:00 -0400

Combination Creates Global Market Leader of Thermal and Precision Flow Management Technologies

Announces Appointment of Paul Mascarenas to its Board of Directors

NOVI, Mich., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM) (the “Company” or “Gentherm”), a global market leader of thermal and precision flow management technologies, today announced it has completed the previously announced combination with Modine’s Performance Technologies business (the “Business”). The transaction was first announced on January 29, 2026.

"Today marks the start of the next phase for Gentherm. Together, we have created a global leader in thermal and precision

Gentherm Completes Combination with Modine’s Performance Technologies Business

Thu, 01 Oct 2026 16:36:00 -0400

Combination Creates Global Market Leader of Thermal and Precision Flow Management Technologies

Announces Appointment of Paul Mascarenas to its Board of Directors

NOVI, Mich., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM) (the “Company” or “Gentherm”), a global market leader of thermal and precision flow management technologies, today announced it has completed the previously announced combination with Modine’s Performance Technologies business (the “Business”). The transaction was first announced on January 29, 2026.

"Today marks the start of the next phase for Gentherm. Together, we have created a global leader in thermal and precision